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Some new compounds 9-(1-aryl-5-methyl-1H-1,2,3-triazol-4-yl)-6-hydroxy-3H-xanthen-3-one 7a-j have been 
synthesized for new fluorescence probe material. Their fluorescence and ultraviolet-visible spectra have been studied. Their 
structures are established by MS, IR and 1H NMR spectral data. The structure of title compound 7c has been identified by 
X-ray diffraction. C22H14C1N3O3, belongs to triclinic system, space group Pī with a = 8.296(4), b = 9.726(5), c = 11.976(6) 
Å, α = 90.953(7), β = 105.081(7), γ = 100.693(8)º, V = 914.7(8)Å3, Z = 2, Dc = 1.466 Mg/m3, F(000) = 416.0 and μ = 0.240 
mm–1. The title compound has a weaker inhibiting HIV-1 protease than indinavir.  
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Fluorescence probes are excellent sensors for 
biomolecules, being sensitive, fast-responding and 
capable of affording high spatial resolution via 
microscopic imaging
1-4
. Many fluorescence probes 
employing fluorescein as the core has been 
developed
5-11
. They have been used in the detection of 
a variety of protein, nucleic acid, cell, HIV-1 
nucleocapsid etc
9,12-14
. Fluorescent compounds have 
been excellent tools for the sensitive and specific 
detection of a variety of analytes. Encouraged by 
these results, we are expanding the general approach 
to different fluorophores for better properties. Almost 
all the currently known electron donor are the 
benzene moiety and little are the heteroatromatic 
moiety. 
In addition to molecules containing 1,2,3-triazole 
nucleus are also important heterocycles and 
pharmacologically active molecules. Hence, they have 
























. Substituted 1,2,3-triazoles are 
often applied as building blocks in designing drugs to 
inhibit the growth, invasion, and migration of cancer 
cells (Scheme I)
22
. Moreover, some of 1,2,3-triazole 
containing compounds such as Cefatrizine and 
Carboxyamidotriazole (Scheme II) have already been 
used in clinics or under clinical evaluation for cancer 




However, there is a little information describing 
compounds containing 3H-xanthen-3-one nucleus  
and 1,2,3-triazole moieties in one molecule. Such 
compounds should be reported for the subject.  
Some novel 9-(1-aryl-5-methyl-1H-1,2,3-triazol- 
4-yl)-6-hydroxy-3H-xanthen-3-one 7a–j were 
synthesized from (2,4-dihydroxyphenyl)-(5-methyl-1-




H NMR spectra were obtained in deuterated 
DMSO (CD3SOCD3) at 300 MHz. Starting materials 




General preparation procedure of 9-(1-aryl-5-
methyl-1H-1,2,3-triazol-4-yl)-6-hydroxy-3H-xanthen- 
3-one derivatives 7a~j following the procedure 
method 
A solution of (1-aryl-5-methyl-1H-1,2,3-triazol-4-
yl)-(2,4-dihydroxy-phenyl)-methanone 6a~j (0.0015 
mol) and resorcinol (0.0018 mol) and 4-methyl-
benzenesulfonic acid (0.011 mol) with stirring in 
25mL round bottomed flask at 110°C under argon for 
6-8 hours. Then reaction mixture was cooled to room 
temperature, a solution of 2g NaOH in 25mL water 
was added under acutely stirred. The reaction mixture 
was heated to solution of solid and was poured into 




25mL water. The pH of the reaction mixture was 
regulated to pH = 5 by glacial acetic acid. The red 
precipitation was separation, filtered, washed with water 




Yields (92%), red powder, m.p. >300°C. IR(KBr): 
3395, 3046, 2919, 2696, 2495, 1967, 1878, 1638, 
1587, 1504, 1459, 1384, 1328, 1262, 1207, 1175, 
1101, 1009, 973, 907, 841, 816, 762, 714, 686,  




HNMR(CD3SOCD3): δ 7.825-7.847(d, 2H, J = 
6.6Hz), 7.685-7.710(m, 3H), 7.532-7.564(d, 2H, J = 
9.6Hz, Xt 1,8-H), 6.753-6.784(d, 2H, J = 9.3Hz, Xt 
2,7-H), 6.709(s, 2H, Xt 4,5-H), 3.6-4.0(b, 1H, -OH), 
2.231(s, 3H, Tz-CH3); HRMS(ESI) Calcd: 
C22H15N3O3 [M+H]
+ 




Yields (90%), red powder, m.p. >300°C. IR(KBr): 
3385, 3065, 2923, 2582, 2508, 1878, 1708, 1639, 
1586, 1501, 1458, 1385, 1330, 1266, 1209, 1180, 
1103, 1009, 976, 939, 907, 845, 818, 760, 728, 693, 




HNMR(CD3SOCD3): δ 7.686-7.713(d, 2H, J = 
8.1Hz, Ar 3,5-H), 7.531-7.561(d, 2H, J = 9.0Hz, Xt 
1,8-H), 7.482-7.510(d, 2H, J = 8.4Hz, Ar 2,6-H), 
6.762-6.793(d, 2H, J = 9.3Hz, Xt 2,7-H), 6.719(s, 2H, 
Xt 4,5-H), 3.6-4.2(b, 1H, -OH), 2.454(s, 3H, Tz-CH3), 
2.206(s, 3H, Ar-CH3); HRMS(ESI) Calcd: 
C23H17N3O3 [M+H]
+ 




Yields (91%), red powder, m.p. >300°C. IR(KBr): 
3422, 3069, 2968, 2921, 2410, 1872, 1812, 1637, 
1588, 1515, 1484, 1456, 1388, 1321, 1275, 1206, 
1167, 1106, 975, 907, 875, 845, 824, 787, 760, 726, 




HNMR(CD3SOCD3): δ 8.030(s, 1H), 7.823(m, 1H), 
7.753(m, 2H), 7.532-7.564(d, 2H, J = 9.6Hz, Xt 1,8-
H), 6.745-6.776(d, 2H, J = 9.3Hz, Xt 2,7-H), 6.710(s, 
2H, Xt 4,5-H), 3.5-3.9(b, 1H, -OH), 2.241(s, 3H) ; 
HRMS(ESI) Calcd: C22H14ClN3O3 [M+H]
+
 404.0796. 




Yields (93%), red powder, m.p. >300°C. IR(KBr): 
3409, 3057, 2970, 2872, 2708, 2573, 2501, 1929, 
1717, 1634, 1607, 1498, 1472, 1406, 1368, 1330, 
1266, 1213, 1182, 1108, 1006, 979, 907, 835, 765, 





HNMR(CD3SOCD3): δ 7.876-7.905(d, 2H,  
J = 8.7Hz, Ar 3,5-H), 7.775-7.804(d, 2H, J = 8.7Hz, 
Ar 2,6-H), 7.521-7.552(d, 2H, J = 9.3Hz, Xt 1,8-H), 
6.731-6.762(d, 2H, J = 9.3Hz, Xt 2,7-H), 6.696(s, 2H, 
Xt 4,5-H), 3.6-4.0(b, 1H, -OH), 2.231(s, 3H, Tz-CH3); 
HRMS(ESI) Calcd: C22H14ClN3O3 [M+H]
+
 404.0796. 




Yields (93%), red powder, m.p. >300°C. IR(KBr): 
3411, 3058, 2965, 2921, 2709, 2580, 2512, 1634, 
1608, 1494, 1472, 1443, 1402, 1367, 1332, 1265, 
1213, 1183, 1157, 1108, 1074, 1005, 980, 907, 835, 





HNMR(CD3SOCD3): δ 7.909-7.939(d, 2H,  
J = 9.0Hz, Ar 3,5-H), 7.802-7.829(d, 2H, J = 8.1Hz, 
Ar 2,6-H), 7.495-7.526(d, 2H, J = 9.3Hz, Xt 1,8-H), 
6.710-6.741(d, 2H, J = 9.3Hz, Xt 2,7-H), 6.669(s, 2H, 
Xt 4,5-H), 3.4-4.2(b, 1H, -OH), 2.229(s, 3H, Tz-CH3); 
HRMS(ESI) Calcd: C22H14BrN3O3 [M+H]
+
 448.0291. 




Yields (85%), red powder, m.p. >300°C. IR(KBr): 
3432, 3061, 2983, 2892, 2711, 2593, 2501, 1908, 
 
 




Scheme II — Chemical structures of containing 1,2,3-triazole 
anticancer agents 
 




1872, 1701, 1638, 1585, 1553, 1501, 1457, 1386, 
1327, 1269, 1206, 1172, 1102, 1035, 1006, 977, 907, 





HNMR(CD3SOCD3): δ 7.628-7.702(m, 2H), 
7.325-7.376(m, 3H), 7.208-7.259(t, 1H, J = 7.5Hz), 
6.714-6.745(d, 2H, J = 9.3Hz, Xt 2,7-H), 6.669(s, 2H, 
Xt 4,5-H), 4.125-4.193(q, 2H, J = 6.6Hz, O-CH2), 
3.6-4.2(b, 1H, -OH), 2.050(s, 3H, Tz-CH3), 1.258-
1.305(t, 3H, J = 7.2Hz, C-CH3); HRMS (ESI) Calcd: 
C24H19N3O4 [M+H]
+ 




Yields (95%), red powder, m.p. >300°C. IR(KBr): 
3428, 3069, 2979, 2932, 2710, 2583, 1893, 1638, 
1613, 1579, 1553, 1518, 1492, 1465, 1416, 1388, 
1330, 1253, 1211, 1181, 1103, 1041, 1002, 975, 905, 





HNMR(CD3SOCD3): δ 7.696-7.725(d, 2H, J = 
8.7Hz, Ar 3,5-H), 7.594-7.626(d, 2H, J = 9.6Hz, Xt 
1,8-H), 7.171-7.201(d, 2H, J = 9.0Hz, Ar 2,6-H), 
6.805-6.836(d, 2H, J = 9.3Hz, Xt 2,7-H), 6.774(s, 2H, 
Xt 4,5-H), 4.099-4.169(q, 2H, J = 6.9Hz, O-CH2), 
3.6-4.2(b, 1H, -OH), 2.169(s, 3H, Tz-CH3), 1.346-
1.396(t, 3H, J = 6.9Hz, C-CH3); HRMS(ESI) Calcd: 
C24H19N3O4 [M+H]
+ 




Yields (95%), red powder, m.p. >300°C. IR(KBr): 
3427, 3071, 2914, 2830, 2446, 1878, 1635, 1600, 
1571, 1514, 1460, 1387, 1315, 1253, 1204, 1165, 
1105, 1039, 998, 973, 905, 840, 756, 725, 665, 627, 





(CD3SOCD3): δ 7.733-7.763(d, 2H, J = 9.0Hz, Ar 3,5-
H), 7.614-7.644(d, 2H, J = 9.0Hz, Xt 1,8-H), 7.212-
7.241(d, 2H, J = 8.7Hz, Ar 2,6-H), 6.817-6.852(d, 2H, 
J = 10.5Hz, Xt 2,7-H), 6.792(s, 2H, Xt 4,5-H), 
3.886(s, 3H, O-CH3), 3.6-4.2(b, 1H, -OH), 2.190(s, 
3H, Tz-CH3); HRMS(ESI) Calcd: C23H17N3O4 
[M+H]
+ 




Yields (86%), red powder, m.p. >300°C. IR(KBr): 
3426, 3059, 2919, 2852, 2475, 1874, 1640, 1583, 
1511, 1464, 1382, 1321, 1261, 1203, 1168, 1106, 963, 





HNMR(CD3SOCD3): δ 8.296-8.324(d, 1H, J = 
8.4Hz), 8.181-8.209(d, 1H, J = 8.4Hz), 8.021-8.042(d, 
1H, J = 6.3Hz), 7.794-7.845(t, 1H, J = 7.5Hz), 7.702-
7.726(t, 2H, J = 3.6Hz), 7.640-7.671(d, 2H, J = 
9.3Hz, Xt 1,8-H), 7.417-.442(d, 1H, J = 7.5Hz), 
6.819-6.850(d, 2H, J = 9.3Hz, Xt 2,7-H), 6.753(s, 2H, 
Xt 4,5-H), 3.6-4.0(b, 1H, -OH), 2.052(s, 3H, Tz-CH3); 
HRMS(ESI) Calcd: C26H17N3O3 [M+H]
+ 
420.1343. 




Yields (87%), red powder, m.p. >300°C. IR(KBr): 
3418, 3058, 2921, 2407, 1918, 1636, 1577, 1510, 
1459, 1428, 1385, 1317, 1270, 1248, 1204,  
1167, 1105, 971, 942, 906, 844, 815, 743, 692, 663, 





(CD3SOCD3): δ 8.454(s, 1H), 8.251-8.281(d, 1H,  
J = 9.0Hz), 8.154(m, 2H), 7.946-7.982(d, 1H,  
J = 10.8Hz), 7.702-7.733(m, 2H), 7.634-7.665(d, 2H, 
J = 9.3Hz, Xt 1,8-H), 6.831-6.862(d, 2H, J = 9.3Hz, 
Xt 2,7-H), 6.792(s, 2H, Xt 4,5-H), 3.2-4.0(b, 1H, -
OH), 2.319(s, 3H, Tz-CH3); HRMS(ESI) Calcd: 
C26H17N3O3 [M+H]
+ 
420.1343. Found: 420.1346.  
X-ray structure determination (Supporting 
Information file) 
The structure of title compound 7c (CCDC 
2034640), C22H14C1N3O3, belongs to triclinic system, 
space group Pī with a = 8.296(4), b = 9.726(5), c = 
11.976(6) Å, α = 90.953(7), β = 105.081(7), γ = 
100.693(8)º, V = 914.7(8)Å
3
, Z = 2, Dc = 1.466 
Mg/m
3




Results and Discussion 
 
Synthesis of the title compound 
Ten new high fluorescence quantum yield 
compounds 9-(1-aryl-5-methyl-1H-1,2,3-triazol-4-yl)-
6-hydroxy-3H-xanthen-3-one 7a-j were synthesized 
by the condensation reaction of (2,4-
dihydroxyphenyl)-(5-methyl-1-aryl-1H-1,2,3-triazol-
4-yl)-methanone 6a-j and resorcinol at fusing in the 
catalytic agent. The route of synthesis is shown in 
Scheme III. 
7a Ar = C6H5, 7b Ar = 4-CH3C6H4, 7c Ar = 3-
ClC6H4, 7d Ar = 4-ClC6H4, 7e Ar = 4-BrC6H4, 7f Ar 
= 2-CH3CH2OC6H4, 7g Ar = 4-CH3CH2OC6H4, 7h Ar 
= 4-CH3OC6H4, 7i Ar = α-C10H7, 7j Ar = β-C10H7.  
The crystal structure of the title compound, 7c 
The structure of the title compound 7c is shown in 
Figure 1. The data of selected bond lengths (Å), bond 
angles (°) and selected dihedral bond torsion angles 
(°) for the target compound 7c is shown (Table I-III, 
Supporting Information file).  




The planes of title compound 7c is shown in 
Figure 2 that plane of Xanthen-3-one ring, 1,2,3-
triazole ring (C(12)-C(13)-C(14)-N(3), 53
o
) and aryl 
ring, 1,2,3-triazole ring(C(18)-C(17)-N(1)-N(2), 58
o
) 
is not on one plane in crystal structure compound 7c.  
These are the interactions of hydrogen bond on the 
molecular stacking [O(2)-H(2) 0.82 H(2)-O(2a) 1.86 
O(2)-H(2)…O(2a) 2.570(3) Ǻ, <O(2)-H(2)…O(2a), 
143.54º ]. A view of H-bond structure for the title 
compound 7c is shown in Figure 3.  
 
The fluorescence excitation and emission spectrum 
determinations of the title compounds, 7a-j 
The fluorescence was taken using SPECTRUM 
ASCII PEDS 1.60 in LS 55( Perkin Elmer, 
American). Excitation was provided at 500 nm. 
Emission was obtained starting from 450 nm to  
700 nm. All the analytes were tested in thesame 
concentration (0.1 mM). The fluorescence excitation 
and emission spectra data of compounds 7a-j in the 
pH = 13.0 and in EtOH is showed in Table IV-V 
(Supporting Information file). 
The pH = 13 is a solution 0.1ML
–1
 NaOH in 
distilled water. The part of the fluorescence emission 
spectra of compounds in EtOH and in the pH = 13.0 is 
showed in Figure 4 and Figure 5. The fluorescence 
images of the fluorescence emission spectra of 
compounds 7a-j in EtOH and in the pH = 13.0 is 
showed in Figure 6 and Figure 7. 
 
 




Figure 1 — Mercury view of the molecular structure for the title 








Figure 3 — The H-bond structure of the compound 7c (PWT drawing 
for the Platon) 
 




The fluorescence emission intensity of title 
compounds is higher than fluorescein in ethanol  
as the solvent, but is lower than fluorescein in a 
NaOH aqueous solution. In alkaline condition, the 
fluorescein is a double negative ion structures, to the 
donor of ring for the electronic effect is stronger, 
fluorescence emission intensity of fluorescein is 
higher than the title compounds. 
The fluorescent excitation wavelength and intensity 
of title compounds is singlet in ethanol as the solvent, 
the maximum intensity peak wavelength range is  
526-529.5nm. When the NaOH aqueous solution as 
solvent, the fluorescent excitation wavelength and 
intensity of title compounds is three groups of peak, 
maximum intensity peak wavelength range is  
478.5-480nm. In ethanol as the solvent, title 
compounds is mainly a neutral molecular structure. 
But in alkaline condition, the structure of title 
compounds is mainly a negative ion and a neutral 
molecular structure. The mainly structure and 
fluorescent excitation wavelength of title compounds 
in different solution condition is shown in Scheme IV.  
 
The ultraviolet-visible spectra determinations of 
the title compounds, 7a-j 
The ultraviolet-visible spectra were taken using 
SPECTRUM ASCII PEDS 1.60 in Cary 100 (Varian 
UV-VIS-NIR). The ultraviolet absorbance spectra 
were obtained starting from 300 nm to 700 nm. All 
the analytes were tested in the same concentration 
(0.1 mM). The ultraviolet-visible spectra data of 
compounds 7a-j in the pH = 13.0 and in EtOH is 
showed in Table VI (Supporting Information file). 
The part of the ultraviolet-visible spectra of 
compounds in the pH = 13.0 and in EtOH is showed 
in Figure 8 and Figure 9.  
 
The initial inhibiting HIV-1 protease 









Figure 5 — A part of the fluorescence spectra of compounds in 









Scheme IV — The structure and fluorescent excitation wavelength of title compounds 7a-j in different solution condition 
 
 
Figure 7 — The fluorescence images of title compounds 7a-j in 
the pH = 13.0 
 






Figure 8 — A part of the ultraviolet-visible spectra of compounds 




Figure 9 — A part of the ultraviolet-visible spectra of 
compounds in EtOH 
 
Test principle: HIV-1 protease in the optimum 
reaction condition and reaction system can be cut 
fluorescently labeled substrates, intensity of 
fluorescence detection enzyme in the reaction product 
to reflect the activity of enzyme. In the reaction 
system to join the sample can be used for screening 
the enzyme inhibitors.  
 
Testing materials and methods 
1 HIV-1 PR sample is made by The National Center 
for Drug Screening appointed antiviral screening 
laboratory-Shanghai Institute of Materia Medica, 
Chinese Academy of Medical Sciences, medical 




2 Processing: The sample is dissolved in DMSO or 
dual steaming water before using, the match into 
the appropriate concentration, five times diluted, 
each a series for five dilution degrees. 
3 The indinavir was used for positive control 
medicine by Glaxo Wellcome, S. A. offer. 




The title compound 7g was diluted and added to in 
the reaction buffer of the substrate contain fluorescent 
mark. Then, the target enzyme gene engineering was 
joined. The mixed solution was incubated under the 
optimum reaction conditions. The fluorescence value 
data was taken using FLUO star Galaxy fluorescence 
spectrometer. 
The IC50 of title compound 7g is 15.23 (ug/ml) 
(40nM, 50) and has a weaker inhibiting HIV-1 PR. 
Test samples under different concentration of 
inhibition rate was showed: 
50(ug/ml) 62.61; 10(ug/ml) 27.81; 2.0(ug/ml) 
27.58; 0.40(ug/ml) 28.18; 0.08(ug/ml) 22.59; 
IC50(ug/ml) 15.23; (indinavir, 10nM, 88.1).  
 
Conclusion 
Ten new high fluorescence quantum yield 
compounds 9-(1-aryl-5-methyl-1H-1,2,3-triazol-4-yl)-
6-hydroxy-3H-xanthen-3-one 7a-j were synthesized. 
The fluorescence emission intensity of title 
compounds is higher than fluorescein in ethanol as the 
solvent, but is lower than fluorescein in a NaOH 
aqueous solution. The title compound has a weaker 
inhibiting HIV-1 protease than indinavir.  
 
Supplementary Information 
Supplementary information is available in the 
website http://nopr.niscair.res.in/handle/123456789/60.  
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